---
title: "High GPX4 Expression Defines an Oxidative-Metabolic, PD-L1/CD47-Low Tumor State in Hepatocellular"
id: "biorxiv-0-high-gpx4-expression-marks-an-oxidative-metabolic-pd-l1-cd47-low-and-stroma"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-0-high-gpx4-expression-marks-an-oxidative-metabolic-pd-l1-cd47-low-and-stroma"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.11.13.766360v1?rss=1"
published_at: "2026-11-22T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# High GPX4 Expression Defines an Oxidative-Metabolic, PD-L1/CD47-Low Tumor State in Hepatocellular
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-0-high-gpx4-expression-marks-an-oxidative-metabolic-pd-l1-cd47-low-and-stroma
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.11.13.766360v1?rss=1)
- **Published At:** 2026-11-22T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The investigators analyzed RNA-sequencing from 366 primary tumors in the TCGA-LIHC PanCancer Atlas cohort to map GPX4 expression against immune, metabolic and stromal features. - Correlations were assessed by Spearman tests with Benjamini-Hochberg correction, then re-estimated after adjusting for tumor purity, CTNNB1 and TP53 mutation status, age and sex. - Higher **GPX4** expression associated with lower **PD-L1** (CD274; rho = -0.34; adjusted rho = -0.37) and lower **CD47** (rho = -0.21), plus reduced macrophage marker CD163 (rho = -0.17) and a fibroblast/extracellular-matrix score (rho = -0.22). - Gene set enrichment analysis (GSEA) of GPX4-high versus GPX4-low tumors showed enrichment for oxidative phosphorylation, mitochondrial programs, fatty-acid, xenobiotic and glutathione metabolism pathways. - The same GSEA indicated depletion of extracellular-matrix, TGF-beta and cell-adhesion gene programs in GPX4-high tumors, consistent with a stroma-poor transcriptional state. - GPX4 showed no meaningful association with a T-cell-inflamed profile (rho = -0.07), CD8 T-cell score (rho = -0.03), cytolytic activity (rho = 0.04) or an NRF2 target-gene score (rho = 0.03); NFE2L2 mRNA itself was inversely correlated with GPX4 (rho = -0.32). - A stage-adjusted Cox model found no survival association for GPX4 (hazard ratio per SD 1.09; 95% CI 0.91–1.29). - The authors emphasized that findings are correlative, derived from a single TCGA cohort, and require external validation plus functional experiments before clinical inference.
## Clinical Analysis & Structured Key Points
[Skip to main content](https://www.biorxiv.org/content/10.64898/2026.11.13.766360v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.11.13.766360v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) New Results Follow this preprint # High GPX4 Expression Marks an Oxidative-Metabolic, PD-L1/CD47-Low and Stroma-Poor Tumor State in Hepatocellular Carcinoma [ View ORCID Profile](http://orcid.org/0000-0001-9526-8445)Prakash Raj Govindaraj, Madu Pascal Akaye doi: https://doi.org/10.64898/2026.11.13.766360 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Prakash Raj Govindaraj 1 Moscow Institute of Physics and Technology; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Prakash%2BRaj%2BGovindaraj%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Govindaraj%20PR&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3APrakash%2BRaj%2BGovindaraj%2B) * [ORCID record for Prakash Raj Govindaraj](http://orcid.org/0000-0001-9526-8445 "Open in new tab") * For correspondence: govindaradzh.p@phystech.edu Madu Pascal Akaye 2 Institute of Personalized Oncology, Sechenov First Moscow State Medical University, Moscow, Russia. * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Madu%2BPascal%2BAkaye%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Akaye%20MP&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AMadu%2BPascal%2BAkaye%2B) * [Abstract](https://www.biorxiv.org/content/10.64898/2026.11.13.766360v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5986195/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.11.13.766360v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5986195/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.11.13.766360v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5986195/1) * [Supplementary material](https://www.biorxiv.org/content/10.64898/2026.11.13.766360v1.supplementary-material)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_data/node:5986195/1) * [Data/Code](https://www.biorxiv.org/content/10.64898/2026.11.13.766360v1.external-links)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_data_code/node:5986195/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.11.13.766360v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5986195/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Glutathione peroxidase 4 (GPX4) protects cancer cells from ferroptosis and is a candidate therapeutic target in hepatocellular carcinoma (HCC). How GPX4 expression relates to the immune and metabolic features of patient tumors is not well characterized. Methods: We analyzed RNA-sequencing data from 366 primary tumors of the TCGA-LIHC PanCancer Atlas cohort (365 with survival data). Associations between GPX4 and ten immune and stress-response markers were tested by Spearman correlation with Benjamini-Hochberg correction, then re-estimated after adjustment for consensus tumor purity, CTNNB1 and TP53 mutation, age and sex. A T-cell-inflamed profile, a CD8 T-cell score and an NRF2 target-gene score, gene set enrichment analysis (GSEA) of GPX4-high versus GPX4-low tumors, and Cox models were added as further tests. Results: Higher GPX4 expression was associated with lower expression of PD-L1 (CD274; rho = -0.34, 95% CI -0.43 to -0.24, p = 2.4 x 10^-11), CD47 (rho = -0.21), the macrophage marker CD163 (rho = -0.17) and a fibroblast/extracellular-matrix score (rho = -0.22). These associations persisted after adjustment (CD274 rho = -0.37 in the fully adjusted model). GSEA showed enrichment of oxidative phosphorylation, mitochondrial, fatty-acid, xenobiotic and glutathione metabolism programs and depletion of extracellular-matrix, TGF-beta and cell-adhesion programs in GPX4-high tumors. GPX4 was not associated with a T-cell-inflamed profile (rho = -0.07), a CD8 T-cell score (rho = -0.03), cytolytic activity (rho = 0.04) or an NRF2 target-gene score (rho = 0.03), although NFE2L2 mRNA was inversely correlated with GPX4 (rho = -0.32). GPX4 expression was not associated with overall survival (stage-adjusted hazard ratio per SD 1.09, 95% CI 0.91-1.29). Conclusions: In TCGA-LIHC, high GPX4 expression marks a metabolically active, PD-L1/CD47-low and matrix-poor tumor state, with no evidence of T-cell exclusion, NRF2 pathway activation or prognostic value. These correlative findings come from a single cohort and require external validation and functional testing. Keywords: hepatocellular carcinoma; ferroptosis; GPX4; PD-L1; CD47; tumor microenvironment; NRF2; gene set enrichment analysis; TCGA ### Competing Interest Statement The authors have declared no competing interest. ## Footnotes * * Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.biorxiv.org/content/10.64898/2026.11.13.766360v1?rss=1#page) [ Previous](https://www.biorxiv.org/content/10.64898/2026.11.12.766137v1 "Bryostatin-1 exploits a developmental signaling vulnerability in MEF2D-rearranged B-cell precursor acute lymphoblastic leukemia") Posted November 22, 2026. [ Download PDF](https://www.biorxiv.org/content/10.64898/2026.11.13.766360v1.full.pdf) Print/Save Options [Download PDF](https://www.biorxiv.org/content/biorxiv/early/2026/11/22/2026.11.13.766360.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.biorxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [Supplementary Material ](https://www.biorxiv.org/content/10.64898/2026.11.13.766360v1.supplementary-material) [ Data/Code](https://www.biorxiv.org/content/early/2026/11/22/2026.11.13.766360.external-links) [ Email](https://www.biorxiv.org/ "Email this Article") [ Share](https://www.biorxiv.org/) High GPX4 Expression Marks an Oxidative-Metabolic, PD-L1/CD47-Low and Stroma-Poor Tumor State in Hepatocellular Carcinoma Prakash Raj Govindaraj, Madu Pascal Akaye bioRxiv 2026.11.13.766360; doi: https://doi.org/10.64898/2026.11.13.766360 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Share This Article: Copy [![Twitter logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.biorxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.13.766360v1%26text%3DHigh%2520GPX4%2520Expression%2520Marks%2520an%2520Oxidative-Metabolic%252C%2520PD-L1%2FCD47-Low%2520and%2520Stroma-Poor%2520Tumor%2520State%2520in%2520Hepatocellular%2520Carcinoma "Share this on Twitter") [![Facebook logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.biorxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.13.766360v1%26t%3DHigh%2520GPX4%2520Expression%2520Marks%2520an%2520Oxidative-Metabolic%252C%2520PD-L1%2FCD47-Low%2520and%2520Stroma-Poor%2520Tumor%2520State%2520in%2520Hepatocellular%2520Carcinoma "Share on Facebook") [![LinkedIn logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.biorxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.13.766360v1%26title%3DHigh%2520GPX4%2520Expression%2520Marks%2520an%2520Oxidative-Metabolic%252C%2520PD-L1%2FCD47-Low%2520and%2520Stroma-Poor%2520Tumor%2520State%2520in%2520Hepatocellular%2520Carcinoma%26summary%3D%26source%3DbioRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.biorxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.13.766360v1%26title%3DHigh%2520GPX4%2520Expression%2520Marks%2520an%2520Oxidative-Metabolic%252C%2520PD-L1%2FCD47-Low%2520and%2520Stroma-Poor%2520Tumor%2520State%2520in%2520Hepatocellular%2520Carcinoma "Share on Mendeley") [ Citation Tools](https://www.biorxiv.org/ "Citation Tools") [ Get QR code](https://connect.biorxiv.org/qr/2026.11.13.766360) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.biorxiv.org/content/10.64898/2026.11.13.766360v1&count=horizontal&via=&text=High%20GPX4%20Expression%20Marks%20an%20Oxidative-Metabolic%2C%20PD-L1/CD47-Low%20and%20Stroma-Poor%20Tumor%20State%20in%20Hepatocellular%20Carcinoma&counturl=www.biorxiv.org/content/10.64898/2026.11.13.766360v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.biorxiv.org/content/early/recent) * [Animal Behavior and Cognition](https://www.biorxiv.org/collection/animal-behavior-and-cognition) (8164) * [Biochemistry](https://www.biorxiv.org/collection/biochemistry) (19027) * [Bioengineering](https://www.biorxiv.org/collection/bioengineering) (15171) * [Bioinformatics](https://www.biorxiv.org/collection/bioinformatics) (46187) * [Biophysics](https://www.biorxiv.org/collection/biophysics) (22958) * [Cancer Biology](https://www.biorxiv.org/collection/cancer-biology) (20389) * [Cell Biology](https://www.biorxiv.org/collection/cell-biology) (27670) * [Clinical Trials](https://www.biorxiv.org/collection/clinical-trials) (138) * [Developmental Biology](https://www.biorxiv.org/collection/developmental-biology) (14305) * [Ecology](https://www.biorxiv.org/collection/ecology) (21661) * [Epidemiology](https://www.biorxiv.org/collection/epidemiology) (2067) * [Evolutionary Biology](https://www.biorxiv.org/collection/evolutionary-biology) (26070) * [Genetics](https://www.biorxiv.org/collection/genetics) (16511) * [Genomics](https://www.biorxiv.org/collection/genomics) (24133) * [Immunology](https://www.biorxiv.org/collection/immunology) (19300) * [Microbiology](https://www.biorxiv.org/collection/microbiology) (43780) * [Molecular Biology](https://www.biorxiv.org/collection/molecular-biology) (18619) * [Neuroscience](https://www.biorxiv.org/collection/neuroscience) (96446)
## Related Clinical Research

- [SLC6A8 creatine transporter identified as an immune pressure–exposed metabolic vulnerability in ac](https://medichelpline.com/clinical-feed/biorxiv-0-the-creatine-transporter-slc6a8-is-an-immune-pressure-exposed-metabolic.md)
- [CD38–NAMPT–p21 signaling drives stress resilience in CLL cells](https://medichelpline.com/clinical-feed/biorxiv-4-cd38-nampt-p21-signaling-promotes-stress-adaptation-in-cll.md)
- [High-fat Diets Reprogram Intestinal Stem Cells and May Raise Colon Cancer Risk](https://medichelpline.com/clinical-feed/medical-news-today-0-high-fat-diets-leave-memory-in-gut-stem-cells-that-may-fuel-colon-cancer.md)
- [Camupepimut KRAS Vaccine Induces Strong Immune Responses in Phase 2 Pancreatic Cancer Trial](https://medichelpline.com/clinical-feed/medical-news-today-0-experimental-pancreatic-cancer-vaccine-shows-promise-in-clinical-trial.md)
- [Psychotropic drug prescribing trends in Dutch nursing home residents with dementia, 2016–2023](https://medichelpline.com/clinical-feed/plos-one-17-trends-in-psychotropic-drug-use-in-nursing-home-residents-with-dementia-and.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.